ASH 2012 CLL Paper Slideshow Summary by Susan ... - CLL Support

CLL Support

22,985 members39,471 posts

ASH 2012 CLL Paper Slideshow Summary by Susan O'Brien and Kanti Rai

AussieNeil profile image
AussieNeilPartnerAdministrator
0 Replies

A slideshow summary of CLL related papers, presented at last year's American Society of Hematology (ASH) Annual Meeting is now available from Clinical Care Options (free registration). It provides a good comparison of how various new drug and new drug combinations work with different classes of CLL patients.

clinicaloptions.com/Oncolog...

Key to Common Abbreviations

CR = Complete Response

DOR = Duration of Response

MRD negative = Minimal Residual Disease negative (i.e can't detect CLL)

ORR = Objective Overall Response (sum of PRs and CRs)

OS = Overall Survial

PD = Progressive Disease

PFS = Progression-Free Survival

PR = Partial Remission

SD = Stable Disease

TTF = Time to Treatment Failure

The purpose of many of these are discussed in the paper: Endpoints for Assessing Drug Activity in Clinical Trials

theoncologist.alphamedpress...

Neil

Written by
AussieNeil profile image
AussieNeil
Partner
To view profiles and participate in discussions please or .
Read more about...

Not what you're looking for?

You may also like...

Dr. Kanti Rai on the Future of CLL Therapy

Friends, This week we have posted an interview with one and only Dr. Kanti Rai when he sat down to...

CLL Society ASH 2020 Day 4 Updates and Wrap-Up Less fun! No hugs. But we are leaving with a lot of treats!

CLL Society ASH 2020 Day 4 Updates and Wrap-Up Dec. 8th was the 4th and final day of ASH 2020, the...

OncLive 9 CLL Videos - Optimizing the Treatment of CLL With Novel Therapies and more Take-home messages from ASH 2021

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for...

Encouraging results from venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen

We've heard that re-treatment with venetoclax is possible. Per the attached image, here's some...

Response and Survival Rates for FCR and Ibrutinib

Those of you who waded through my post yesterday on clonal evolution will be glad to know this is a...